CWA Asset Management Group LLC Purchases 1,349 Shares of Kenvue Inc. (NYSE:KVUE)

CWA Asset Management Group LLC raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 10.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,841 shares of the company’s stock after acquiring an additional 1,349 shares during the period. CWA Asset Management Group LLC’s holdings in Kenvue were worth $332,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. SRS Capital Advisors Inc. boosted its holdings in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the period. Clarity Asset Management Inc. bought a new stake in Kenvue during the 4th quarter valued at approximately $45,000. SBI Securities Co. Ltd. bought a new stake in Kenvue during the 4th quarter valued at approximately $46,000. Deseret Mutual Benefit Administrators boosted its position in shares of Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after acquiring an additional 568 shares during the period. Finally, Versant Capital Management Inc boosted its position in shares of Kenvue by 77.9% in the first quarter. Versant Capital Management Inc now owns 3,415 shares of the company’s stock valued at $82,000 after acquiring an additional 1,495 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 0.1%

NYSE KVUE opened at $21.39 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The stock’s 50 day moving average is $22.99 and its two-hundred day moving average is $22.41. The company has a market capitalization of $41.03 billion, a price-to-earnings ratio of 38.88, a PEG ratio of 3.32 and a beta of 0.98. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. Kenvue’s quarterly revenue was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.28 EPS. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.83%. Kenvue’s dividend payout ratio is presently 149.09%.

Analyst Ratings Changes

Several research firms have recently weighed in on KVUE. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Barclays increased their price target on shares of Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a report on Monday, May 12th. Piper Sandler increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 target price for the company. Finally, Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective for the company. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.